DAX24.340 +0,2%Est505.746 -0,1%MSCI World4.343 -0,1%Top 10 Crypto10,94 -5,7%Nas23.593 -0,1%Bitcoin74.306 +0,2%Euro1,1776 ±0,0%Öl60,64 -2,6%Gold4.533 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Novo Nordisk A3EU6F Rheinmetall 703000 DroneShield A2DMAA Tesla A1CX3T Amazon 906866 Allianz 840400 Nike 866993 BYD A0M4W9 Bayer BAY001 D-Wave Quantum A3DSV9 Lufthansa 823212 Deutsche Telekom 555750 Alphabet A (ex Google) A14Y6F Microsoft 870747
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt vor Weihnachten etwas höher -- Alphabet kauft Intersect -- Novo Nordisk, D-Wave, Lufthansa, Palantir, TUI, Microsoft, Bitcoin, Gold im Fokus
Top News
Rentenfonds und Anleihen-ETF: Unterschiede, Kosten und Auswahlkriterien Rentenfonds und Anleihen-ETF: Unterschiede, Kosten und Auswahlkriterien
Consorsbank-Depot zu teuer? Mit diesem Broker sparst Du dauerhaft Gebühren Consorsbank-Depot zu teuer? Mit diesem Broker sparst Du dauerhaft Gebühren
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

VolitionRX Aktie

Kaufen
Verkaufen
0,2500 USD -0,0073 USD -2,84 %
nachbörslich
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.26,28 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA12B6K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS9286611077

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVNRX

VolitionRX Aktien News

DatumMeistgelesen
PR NewswireVolition Issues Business Review 2025
PR NewswireVolition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment
PR NewswireVolition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer
PR NewswireVolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis
PR NewswireVolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use
PR NewswireVolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update
PR NewswireVolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update
PR NewswireVolition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs
PR NewswireVolition Sponsors Upcoming GenomeWeb Webinar
PR NewswireVolition Signs Co-Marketing and Services Agreement with Hologic
PR NewswireVolition Signs First Human Out Licensing Deal
PR NewswireVolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update
PR NewswireVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update
PR NewswireNu.Q® Discover Expands Global Adoption and Epigenetic Innovation
PR NewswireVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes
PR NewswireVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure
PR NewswireVolition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties
PR NewswireVolitionRx Limited Announces Successful Detection of Nucleosomes in Cats
PR NewswireVolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update
BenzingaVolitionRX Earnings Preview
PR NewswireVolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update
PR NewswireVolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption
PR NewswireVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
PR NewswireVolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
PR NewswireVolition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
PR NewswireVolition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
PR NewswireVolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update
PR NewswireVolition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry
PR NewswireVolition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer
PR NewswireVolition Proudly Sponsors the 44th ISICEM Congress
PR NewswireVolition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems
PR NewswireVolition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test
PR NewswireVolition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time
PR NewswireVolition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
PR NewswireVolition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
PR NewswireVolition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
PR NewswireLarge clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
PR NewswireVolition Issues Business Review 2024
PR NewswireVolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
PR NewswireStudy shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

VolitionRX News

VolitionRX News: auf dieser Seite finden Sie alle VolitionRX News und Nachrichten zur VolitionRX Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch VolitionRX News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um VolitionRX News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.